

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
14 February 2002 (14.02.2002)

PCT

(10) International Publication Number
WO 02/11707 A2

(51) International Patent Classification⁷: **A61K 31/00**

(74) Agents: **SAMA, Daniele et al.**; Sama Patents, Via G.B. Morgagni 2, I-20129 Milano (IT).

(21) International Application Number: **PCT/EP01/08734**

(22) International Filing Date: **27 July 2001 (27.07.2001)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
MI2000A 001848 8 August 2000 (08.08.2000) IT

(71) Applicant (*for all designated States except US*): **NICOX S.A.** [FR/FR]; 1900, rue des Crêtes, F-06560 Sophia Antipolis (FR).

(81) Designated States (*national*): AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, YU, ZA.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **DEL SOLDATO, Piero** [IT/IT]; Via Toti, 22, I-20052 Monza (IT). **BENE-DINI, Francesca** [IT/IT]; Via Padova, 286, I-20100 Milano (IT).



WO 02/11707 A2

(54) Title: **DRUGS FOR INCONTINENCE**

(57) Abstract: Use in the incontinence of one or more of the following classes of drugs selected from the following: B) salified and non salified nitric oxide-donor drugs, of formula: A - X₁ - N(O)₂, B') nitrate salts of drugs used for the incontinence, and which do not contain in the molecule a nitric oxide donor group; C) organic or inorganic salts of compounds inhibiting phosphodiesterases.

DRUGS FOR INCONTINENCE

* * * * *

The present invention relates to the use of classes of drugs, optionally mixtures thereof, for the urinary incontinence therapy.

More specifically, the invention relates to the use in the urinary incontinence therapy of one or more of the following compounds as defined hereunder, characterized in that they have a good efficacy in the urinary incontinence treatment combined with low side effects.

It is well known that the urinary incontinence can be considered a micturition control trouble consequent on a lesion or a dysfunction of the low urinary ducts. In particular the smooth musculature of the urinary bladder, called detrusor muscle, and the internal urethral sphincters (smooth musculature) and external (striated musculature) are involved. See for example Ferguson D. and Christopher N., Urinary Bladder Function and Drug Development, Trends in Pharmacological Sciences, 1996, 17, 161-165. In this publication it is mentioned that various kinds of incontinence exist characterized by different causes and symptoms. In particular it can be mentioned:

- incontinence from efforts which consists in the loss of small amounts of urine as a consequence of an intrabdominal pressure increase, due to, for example, a cough or an effort. It is due to the change of the vesico-urethral angle and to the musculature relaxation of the urethral sphincters. It is frequent above all in multipara women;
- incontinence from urgency which consists in the inability to control the bladder and it appears with a sudden and impelling stimulus to urinate. It is due to intermittent contractions of the bladder musculature without evident causes (detrusor instability) or consequent on interstitial cystitis or other inflammatory phenomena which cause bladder hyperexcitability. It seems that in all these cases alterations of the bladder innervation are present;

- incontinence from bladder overrelaxation which appears in the cases of chronic urinary retention due to obstructive causes. The bladder never empties itself completely with consequent continuous loss of small amounts of urine;
- total incontinence which consists in the complete lack of control on the bladder due to inability to control the sphincters. It is a consequence of serious neurological damages.

In the prior art the available therapies are based on three different approaches - see for example the above article and Anderson K.E., Pharmacology of Lower Urinary Tract Smooth Muscles and Penile Erectile Tissues, Pharmacological Reviews, 1993, 45, 253-308:

- reduction of the detrusor activity,
- modification of the sensory nervous transmission,
- modification of the urethral resistances.

According to the first approach, the detrusor contraction is stimulated by the parasympathetic system and acetylcholine is the main mediator. Therefore to reduce the bladder hyperactivity anticholinergic drugs are used which are effective but of limited use owing to the anticholinergic activity at systemic level. Indeed they cause side effects such as for example fauces dryness, constipation and tachycardia. If one considers that the bladder irritability is often associated to obstructive bladder pathologies, the administration of anticholinergic drugs can potentially cause crises of acute urinary retention.

For example anticholinergic drugs such as oxybutynin or tolterodine are quite effective. Their use is however limited by the side effects typical of anticholinergic agents (fauces dryness, dimmed sight, etc.) Occasionally patients under treatment with said products can also have cardiac rhythm troubles. In patients affected by glaucoma, a worsening of the pathology can happen, furthermore in old patients with prostatic hypertrophy a worsening of the urinary retention can take place.

Another pharmacological approach for reducing the detrusor activity considers the use of drugs which facilitate the opening of the channels of potassium, of calcium antagonists and of relaxing drugs of the smooth musculature.

Also in this case there are side effects, such as for example the arising of a marked hypotensive action due to the aspecific effect of vasodilation induced by these drugs.

The administration of β -agonist drugs induces an increase of the bladder capacity, but their use is limited by the serious side effects affecting the cardiovascular system.

A further pharmacological approach for reducing the bladder hyperactivity is the use of antidepressant drugs, but also with these therapeutic aids there are serious side effects affecting the cardiovascular system (orthostatic hypotension, arrhythmia).

Another pharmacological method for reducing the detrusor activity consists in the use of the prostglandin synthesis inhibitors which have been experimented in some cases of detrusor hyperactivity and enuresis with promising results. Also in this case the side effects which have been noticed have been significant. The use of these drugs is based on the fact that several prostglandines are synthesized at bladder level as a consequence of nervous stimulation and some of them would have the function of mediators of the detrusor muscle contractions. Some prostglandines would be furthermore involved in phenomena of incontinence from urgency and bladder hyperactivity noticed during some inflammatory pathologies of the urinary tract.

The non steroidal antiinflammatory drugs are potentially useful for reducing the limit of excitability of the urinary bladder, and are therefore effective in the cases of detrusor instability. Unfortunately they show the drawback that at active doses they are poorly tolerated especially at the gastrointestinal apparatus level.

The NO enzyme synthetase inhibitors could prevent the bladder hyperexcitability and hyperalgesia consequent on inflammatory phenomena such as interstitial cystitis; see Rice A.S.C., Topical Spinal Administration of a Nitric Oxide Synthase Inhibitor Prevents the Hyper-Reflexia Associated with a Rat Model of Persistent Visceral Pain, Neuroscience Letters, 1995, 187, 111-114. However, at present, therapeutically usable drugs of this kind do not exist because of the corresponding aspecificity of their pharmacological profile.

The second approach which consists in the modification of the sensory nervous transmission (in the cases when the urinary incontinence derives from lesions of the nervous system) implies the use of active drugs on the neurotransmission, for example of gamma-aminobutyric acid (GABA), or peptides, or purines, which are important neurotransmitters at the urinary ducts level.

Also clinical studies which use capsaicin by intravesical instillation with sometimes positive results are known. However this treatment has limited clinical applications due to its transitory effect and besides obtainable only by local administration.

The third approach is based on the fact that at the urethra level the musculature tone is mediated by different neurotransmission systems, for example the adrenergic one by stimulation of the α receptors. To modify the urethral resistances α -agonist drugs are used with sometimes satisfactory results; they increase the pressure bearable by the urethra. However the use of these compounds is contraindicated in the case of obstructive pathologies of the bladder, in which even alpha-antagonist drugs are used. In these cases it is indeed frequent that an hyperactivity of the sphincters takes place, which hinders the regular bladder emptying, causing incontinence from urgency. Also in this case, as well as in the first above described approach, serious side effects of hypotensive type bound to the α -antagonist activity affecting the cardiocirculatory apparatus level are to be pointed out.

Up to now the commercially available drugs solve the problem only in a limited number of cases but generally inducing side effects also of a certain seriousness.


Good results have been obtained with products described in patent application WO 98/09948 in the name of the Applicant wherein nitroxyderivatives of particular classes of non steroidal antinflammatory drugs are used. These products are very good drugs for the incontinence treatment with low side effects, however they have the drawback to have to be mainly administered by os. When a parenteral administration is necessary (cases of bad absorption, seriously ill hospitalized patients where the administration by os cannot

be carried out), it has been found that the products mentioned in said application are not administrable by parenteral route.

The Applicant has unexpectedly and surprisingly found compounds effective in the incontinence treatment and giving lower side effects, and are administrable also parenterally, therefore overcoming the drawbacks of the prior art.

An object of the present invention is the use in the incontinence of one or more of the following classes of drugs selected from the following:

- A) nitric oxide donor drugs, optionally salified, of formula:




wherein A, X_1 , Z have the meaning defined below;

- B') nitrate salts of drugs used for the incontinence and which do not contain in the molecule a nitric oxide donor group;

- C) organic or inorganic salts of compounds inhibiting phosphodiesterases;

in the compounds of general formula:




z is an integer and is 1 or 2, preferably 2;

A = $R(COX_u)_t$ and wherein t is an integer 0 or 1; u is 0 or 1;

X = O, NH, NR_{1c} wherein R_{1c} is a linear or branched C_1-C_{10} alkyl;

X_1 is the following bivalent linking group:



wherein:

nIX is an integer in the range 0-3, preferably 1;

nIIX is an integer in the range 1-3, preferably 1;


R_{TIX} , $R_{TIX'}$, R_{TIIX} , $R_{TIIX'}$, equal to or different from each other are H or linear or branched C_1-C_4 alkyl; preferably R_{TIX} , $R_{TIX'}$, R_{TIIX} , $R_{TIIX'}$ are H;

Y is a heterocyclic ring containing one or two nitrogen atoms, optionally one oxygen or sulphur atom, said saturated, unsaturated or aromatic ring, having 5 or 6 atoms;


R is selected from the following groups:

Group I) wherein $t = 1$ and $u = 1$

Ia)



Ib)



wherein:

R_1 is the $OCOR_3$ group; wherein R_3 is methyl, ethyl or linear or branched C_3 - C_5 alkyl, or the residue of a heterocycle with only one ring having 5 or 6 atoms which can be aromatic, partially or totally hydrogenated, containing one or more heteroatoms independently selected from O, N and S;

R_2 is hydrogen, hydroxy, halogen, linear or branched when possible C_1 - C_4 alkyl; a linear or branched when possible C_1 - C_4 alkoxy; a linear or branched when possible C_1 - C_4 perfluoroalkyl, for example trifluoromethyl; nitro, amino, mono- or di- (C_{1-4}) alkylamino;

nI is an integer 0 or 1;


preferably in the compounds of formula Ia) X is equal to O or NH, R_1 is acetoxy, preferably in ortho position with respect to $-CO-$, R_2 is hydrogen; preferably X_1 is the linking group

(B) wherein $R_{TIX} = R_{TIX'} = R_{TIX''} = R_{TIX'''} = H$, $n_{IX} = n_{IIX} = 1$;


Preferably in the compounds of formula Ib) $R_3 = CH_3$, $nI = 0$, X is equal to O, X_1 is as above defined for Ia); in this case Ib) is the residue of the acetylsalicylsalicylic acid;

Group II, wherein $t = 1$, $u = 1$

IIa)



IIb)



wherein:

R_{II5} is H, linear or branched when possible C_1 - C_3 alkyl;

R_{II6} has the same meaning as R_{II5} , or when R_{II5} is H it can be benzyl;


R_{II1} , R_{II2} and R_{II3} can independently be hydrogen, linear or branched when possible C_1 - C_6 alkyl, or linear or branched when possible C_1 - C_6 alkoxy, or Cl, F, Br;

R_{II4} is R_{II1} or bromine;

the compounds wherein R_{II1} , R_{II4} are hydrogen and R_{II2} and R_{II3} are chlorine in ortho position with respect to NH are preferred; R_{II5} and R_{II6} are H, X is equal to O, and X_1 is as above defined for the compounds of formula Ia);


IIb) is the residue of the 2-[(2-methyl-3-(trifluoromethyl)phenyl]amino]-3-pyridincarboxylic acid and when the -COOH group is present the compound is known as flunixin;

Group III) wherein $t = 1$, $u = 1$ and R is




wherein:


R_{2a} and R_{3a} are H, linear or branched when possible, substituted or not, C_1 - C_{12} alkyl or allyl, with the proviso that if one of the two is allyl, the other is H; preferably R_{2a} is H, C_1 - C_4 alkyl, R_{3a} is H; R_{1a} is selected from




(II)




(XXI)




(IV)




(XXXV)




(VI)




(VII)




(VIII)



(IX)




(X)




(III)


IIID) R_{1a} corresponds to the following formulas:




(IIIa)




(XXX)




(XXXI)




(XXXII)




(XXXIII)



(XXXVI)



(XXXVII)



(XII)

wherein the meanings are the following:

- when R_{1a} is as defined in formula (IV), Ketoprofen residue:

R_{III1} is H, SR_{III3} wherein R_{III3} contains from 1 to 4 carbon atoms, linear or branched when possible;

R_{III2} is H, hydroxy;

the compounds wherein R_{III1} and R_{III2} are H, R_{3a} is H, and R_{2a} is methyl, $X = O$, are preferred;

- when R_{1a} is as defined in formula (XXI), carprofen residue:

R_{xx10} is H, linear or branched when possible alkyl from 1 to 6 carbon atoms, C_1-C_6 alkoxy carbonyl linked to a C_1-C_6 alkyl, C_1-C_6 carboxyalkyl, C_1-C_6 alkanoyl, optionally substituted with halogens, benzyl or halobenzyl, benzoyl or halobenzoyl;

R_{xx1} is H, halogen, hydroxy, CN, C_1-C_6 alkyl optionally containing OH groups, C_1-C_6 alkoxy, acetyl, benzyloxy,

SR_{xx12} wherein R_{xx12} is C_1-C_6 alkyl; C_1-C_3 perfluoroalkyl; C_1-C_6 carboxyalkyl optionally containing OH groups, NO_2 , amino; sulphamoyl, di-alkyl sulphamoyl with C_1-C_6 alkyl, or difluoroalkylsulphonyl with C_1-C_3 alkyl;

R_{xx11} is halogen, CN, C_1-C_6 alkyl containing one or more OH groups, C_1-C_6 alkoxy, acetyl, acetamido, benzyloxy,

SR_{III3} being R_{III3} as above defined, C_1-C_3 perfluoroalkyl, hydroxy, C_1-C_6 carboxyalkyl, NO_2 , amino, mono- or di-alkyl-amino C_1-C_6 ; sulphamoyl, di-alkyl sulphamoyl C_1-C_6 , or di-fluoroalkylsulphamoyl as above defined; or R_{xx1} together with R_{xx11} is a C_1-C_6 alkylenedioxy;

the compounds are preferred wherein R_{xx10} is H, the linking group is in position 2, R_{xx1} is H, R_{xx11} is

chlorine and is in para position with respect to nitrogen;

R_{3a} is H, R_{2a} is methyl and X is O;

- when R_{1a} is as defined in formula (XXXV), tiaprofenic acid residue;

Ar is phenyl, hydroxyphenyl optionally mono- or polysubstituted with halogen, alkanoyl and alkoxy C_1-C_6 , C_1-C_6 , preferably C_1-C_3 , trialkyl, cyclopentyl, cyclohexyl, cycloheptyl, heteroaryl, preferably thienyl, furyl optionally containing OH, pyridyl;

the preferred compounds of (XXXV) are those wherein Ar is phenyl, R_{3a} is H, R_{2a} is methyl and X is O;

- when R_{1a} is as defined in formula (II), suprofen residue,

of which the preferred one has been indicated, wherein R_{3a} is H, R_{2a} is methyl and X = O, as described and obtained in USP 4,035,376 herein incorporated by reference;

- when R_{1a} is as defined in formula (VI), R is the residue of indoprofen when R_{2a} = H and R_{3a} = CH_3 ; of indobufen when R_{2a} is equal to H and R_{3a} = C_2H_5 ; X = O, as described and obtained according to USP 3,997,669 herein incorporated by reference;

- when R_{1a} is as defined in formula (VIII), R is the etodolac residue when R_{2a} = R_{3a} = H and X = O, as described and obtained according to USP 3,843,681 herein incorporated by reference;

- when R_{1a} is as defined in formula (VII), R is the fenoprofen residue when R_{3a} = H, R_{2a} = CH_3 and X = O, as described and obtained according to USP 3,600,437 herein incorporated by reference;


- when R_{1a} is as defined in formula (III), R is the fenbufen residue when R_{2a} = R_{3a} = H and X = O, as described and obtained according to USP 3,784,701 herein incorporated by reference;

- when R_{1a} is as defined in formula (IX), R is the flurbiprofen residue when R_{3a} = H, R_{2a} = CH_3 , X = O;

- when R_{1a} is as defined in formula (X) R is the tolmetin residue when R_{2a} = R_{3a} = H, X = O, as described and obtained according to FR 1,574,570 herein incorporated by reference;

In group IIID) R_{1a} corresponds to the following formulas:


- IIIa), when $R_{2a} = H$ and $R_{3a} = CH_3$, the pranoprofen residue is obtained: α -methyl-5H-[1]benzopyran-[2,3-b]pyridin-7-acetic acid; the preferred compound has $R_{2a} = H$, $R_{3a} = CH_3$, $u = 1$ and $X = O$;
 - (XXX), when $R_{2a} = H$ and $R_{3a} = CH_3$, the bermoprofen residue is obtained: dibenz[b,f]oxepin-2-acetic acid; the preferred compound has $R_{2a} = H$, $R_{3a} = CH_3$, $u = 1$ and $X = O$.
 - (XXXI), when $R_{2a} = H$ and $R_{3a} = CH_3$, R is the radical of the compound CS-670: 2-[4-(2-oxo-1-cyclohexyliden methyl) phenyl]propionic acid; the preferred compound has $R_{2a} = H$, $R_{3a} = CH_3$, $u = 1$ and $X = O$;
 - (XXXII), when $R_{2a} = R_{3a} = H$, the Pemedolac residue is obtained; the preferred compound has $R_{2a} = R_{3a} = H$, $u = 1$ and $X = O$;
 - (XXXIII), when $R_{2a} = R_{3a} = H$, the pirazolac residue is obtained: 4-(4-chlorophenyl)-1-(4-fluorophenyl)-3-pyrazolic acid derivatives;
The preferred compounds have $R_{2a} = R_{3a} = H$, $u = 1$ and $X = O$;
 - (XXXVI), when $R_{2a} = H$, $R_{3a} = CH_3$, the zaltoprofen residue is obtained; when the residue is saturated with a hydroxyl or amino group, or with the carboxylic function the compounds are known as dibenzothiepine derivatives; the preferred compounds have $R_{2a} = H$, $R_{3a} = CH_3$, $u = 1$ and $X = O$;
 - (XXXVII), when $R_{2a} = R_{3a} = H$ the mofezolac residue is obtained: 3,4-di(p-methoxyphenyl)isoxazol-5-acetic acid when the residue is CH_2-COOH ; the preferred compounds have $R_{2a} = R_{3a} = H$, $t = 1$ and $X = O$;
 - (XII), when $R_{2a} = R_{3a} = H$ the bromfenac residue is obtained: 2-amino-3-(4-bromobenzoyl)benzeneacetic acid; the preferred compounds have $u = 1$, $t = 1$, $X = O$, $R_{2a} = R_{3a} = H$; or $t = 0$;
- in group IV) wherein $t = 1$, $u = 1$, R is




wherein:

R_{IVd} and R_{IVd1} are at least one H and the other a linear or branched when possible $C_1 - C_6$, preferably C_1 and C_2 alkyl, or difluoroalkyl with the alkyl from 1 to 6 carbon atoms, C_1 is preferred, or R_{IVd} and R_{IVd1} form together a methylene group;


R_{IV} has the following meaning:



(II)



(X)



(III)

wherein the compounds of group IV) have the following meanings:

- in formula (II)

R_{IV-ii} is $C_1 - C_6$ alkyl, $C_3 - C_7$ cycloalkyl, $C_1 - C_7$ alkoxy-methyl, $C_1 - C_3$ trifluoroalkyl, vinyl, ethynyl, halogen, $C_1 - C_6$ alkoxy, difluoroalkoxy, with $C_1 - C_7$ alkyl, $C_1 - C_7$ alkoxy-methoxy, alkylthiomethoxy with $C_1 - C_7$ alkyl, alkyl methylthio with $C_1 - C_7$ alkyl, cyan, difluoromethylthio, phenyl- or phenylalkyl substituted with $C_1 - C_6$ alkyl; preferably R_{IV-ii} is CH_3O- , R_{IVd} is H and R_{IVd1} is CH_3 , and it is known as naproxen residue;


$X = O$ and X_1 is as above defined for Ia);

- in formula (X), of which the loxoprofen residue, described in USP 4,161,538 herein incorporated by reference, has been indicated, the compounds wherein R_{IVd}

is H and R_{IVd1} is CH_3 , $X = O$ and X_1 is as above defined for Ia) are preferred;


in formula (III):

R_{IV-III} is a C_2-C_5 alkyl, optionally branched when possible, C_2 and C_3 alkyloxy, allyloxy, phenoxy, phenylthio, cycloalkyl from 5 to 7 carbon atoms, optionally substituted in position 1 by a C_1-C_2 alkyl; it is preferred the compound wherein R_{IV-III} is




and $R_{IVd} = H$, R_{IVd1} is CH_3 , compound known as ibuprofen residue; $X = O$ and X_1 is as above defined for Ia);


Group V)




(VII)




(IX)




(IV)




(V)



(III)




(II)




(LX)


Group VE)




(X)




(XI)



(XIII)



(XXXX)



(XXXXXI)


in group V), the compounds have the following meanings:


- when R is formula (II),
 R_{VII} is H or a linear or branched when possible C_1-C_4 alkyl;
 R_{VII-1} is R_{VII} , or a linear or branched when possible C_1-C_4 alkoxy; Cl, F, Br; the position of R_{VII-1} being ortho, or meta, or para;
 the residue of the known Ketorolac is preferred, wherein R_{VII} and R_{VII-1} are H, and $A = R$ (A being the group of the formula $A-X_1-NO_2$) and $t = 0$;
- when R is formula (V),
 of which the residue of the known tenidap has been indicated, as described and obtained in USP 4,556,672 herein incorporated by reference;
 in these compounds of formula (V) $A = R$ and $t = 0$;
- when R is formula (VII),
 of which the residue of the known tenoxicam has been indicated, A is RCO, $t = 1$ $u = 0$ or A is R and $t = 0$, as described and obtained in DE 2,537,070 herein incorporated by reference;
- when R is formula (IX),
 wherein $A = R$ and $t = 0$, or $A = RCO$ with $t = 1$ and $u = 0$, the residue of the known piroxicam has been indicated, as described and obtained in USP 3,591,584 herein incorporated by reference;
- when R is formula (III)
 wherein $A = RCOO$, $t = 1$ and $u = 0$ or 1; or $t = 0$ and $A = R$, of which the residue of the known nabumetone has been indicated, as described and obtained in USP 4,061,779 herein incorporated by reference;
- when R is formula (IV)
 wherein $A = RCOO$, $t = 1$ and $u = 1$,

of which the indomethacin residue has been indicated, as described and obtained in USP 3,161,654, herein incorporated by reference;

- when R = formula (LX) and in $(\text{COX}_u)_t$, $u = t = 1$ and X is oxygen, the precursor compound is known as sulindac;
 - when R is formula (X), the X residue is known as meloxicam; the preferred compounds are those wherein $A = \text{RCO}$, $t = 1$ and $u = 0$;
 - when R is formula (XI) the residue is known as ampiroxicam when the termination is $-\text{CH}(\text{CH}_3)\text{OCOC}_2\text{H}_5$; the preferred compounds have $A = \text{RCO}$, $t = 1$ and $u = 0$;
 - when R is formula (XIII) and the valence is saturated with H, the residue derives from lornoxicam; the preferred compounds have $A = \text{RCO}$, $t = 1$ and $u = 0$;
 - when R is formula (XXXX) and the valence is saturated with H the compound known as paracetamol is obtained, as described and obtained in USP 2,998,450 herein incorporated by reference;
 - when R is formula (XXXXI) and the valence is saturated with H, the compound known as Tramadol is obtained, as described and obtained in USP 3,652,589;
- the preferred compounds according to the present invention obtainable with the radicals corresponding to the formulas (XXXX) and (XXXXI) have $A = \text{RCO}$, $t = 1$ and $u = 0$.

Preferably Y is selected from the following:





Preferably Y is an aromatic ring having 6 atoms, containing one nitrogen atom, said aromatic ring having the two free valences in position 2 and 6.

The preferred of Y is Y12 (pyridyl) substituted in position 2 and 6. The bonds can be also in a non symmetric position, for example Y12 (pyridyl) can be substituted also in position 2 and 3; Y1 (pyrazol) can be 3,5-disubstituted.

The X_1 precursors as defined by formula (B), wherein the free valence of the oxygen is saturated with H and the free valence of the end carbon is saturated with either a carboxylic or hydroxyl group, are commercially available compounds or they can be obtained by known methods of the prior art.

The compounds containing R of group I of the type Ia) are described in patent application WO 92/01668 wherein also the preparation methods are mentioned. This patent is herein incorporated by reference. The compounds of type Ib) are for example prepared by using the method indicated in The Merck Index, XI ed., 1989, pag. 16, No. 95 for the acetylsalicylsalicylic acid residue. The modifications of the compounds of formula Ib) can be obtained by using the processes mentioned in patent application WO 92/01668.

The compounds wherein R is of group II) are described in patent application WO 94/04484 and USP 3,558,690 wherein also the preparation methods are indicated. These patents are herein incorporated by reference.

The starting compound of IIb), when the valence is saturated with -COOH (flunixin), is obtained according to USP 3,337,570 and USP 3,689,653, both herein incorporated by reference. The compounds containing the substituents mentioned in the previous patents are equivalent to flunixin.

The compounds wherein R is of group III) are described and obtained by the processes mentioned in the following patents:

patent application PCT/EP/93 03193; for the compounds of formula (IV) see also USP 3,641,127; for the compounds of formula (XXI) see also USP 3,896,145; for the compounds of formula (IX) flurbiprofen residue see also USP 3,755,427; for the compounds of formula (II) see also USP 4,035,376; for the compounds of formula (VI) see also USP 3,997,669; for the compounds of formula (VIII) see also USP 3,843,681; for the compound of formula (VII) see also USP 3,600,437; for the compounds of formula (III) see also USP 3,784,701. All these mentioned patents are herein incorporated by reference.

The procedures for the preparation of the compounds of class IIID) are the following:

The residue IIIa) is obtained by preparing the acid compound according to USP 3,931,205, the valence is saturated with $-\text{CH}(\text{CH}_3)-\text{COOH}$. The compounds containing the substituents mentioned in the previous patent are equivalent to pranoprofen. The residue (XXX) is prepared through the compound with the group $-\text{CH}(\text{CH}_3)-\text{COOH}$ (bermoprofen) according to USP 4,238,620 herein incorporated by reference. Other equivalent products are described in the above mentioned patent.

The residue (XXXI) is prepared by starting from the corresponding acid $-\text{CH}(\text{CH}_3)-\text{COOH}$ according to USP 4,254,274. Equivalent compounds are described in the same patent.

The residue (XXXII) is prepared according to EP 238,226 herein incorporated by reference, when the valence is saturated with $-\text{CH}_2-\text{COOH}$. Equivalent products are reported in said patents as 1,3,4,9 tetrahydropyran [3,4-b] indol-1-acetic substituted acids.

The residue (XXXIII) is prepared from pirazolac and the valence is saturated with $-\text{CH}_2-\text{COOH}$, as indicated in EP 54,812 herein incorporated by reference. Equivalent products are described in said patent.

The residue (XXXVI) is prepared according to UK 2,035,311 herein incorporated by reference, by starting from zaltoprofen and having the $-\text{CH}(\text{CH}_3)-\text{COOH}$ termination. Equivalent products are described in said patent.

The process for preparing the residue (XXXVII) is obtained starting from mofezolac and it is prepared according to EP 26,928. Equivalent products are reported in the same patent.

The compounds wherein R is of group IV) are described in GB patent application 2,283,238, wherein also the preparation methods are indicated; this patent is herein incorporated by reference.

In group IV) the compounds can also be obtained: for the compounds of formula (II) using USP 3,904,682; the compounds of formula (X) according to USP 4,161,538; the compounds of formula (III) according to USP 3,228,831. The herein mentioned patents are incorporated in the present application by reference.

In group V) the compounds can also be obtained: for the compounds of formula (II) using USP 4,089,969 herein incorporated by reference; the compounds of formula (V) can be obtained according to USP 4,556,672 herein incorporated by reference.

The residue (X) is prepared according to the German patent 2,756,113. Equivalent products are described in said patent.

The residue (XI) is prepared according to EP 147,177, herein incorporated by reference, starting from ampiroxicam having the termination $-\text{CH}(\text{CH}_3)\text{OCOOC}_2\text{H}_5$. Equivalent products are described in said patent.

The residue (XII) is prepared according to J. Med. Chem., vol. 27 No. 11, -Nov. 1984, Walsh et Al. "Antiinflammatory Agents. 3. Synthesis and Pharmacological Evaluation of 2-amino-3-benzoylphenylacetic Acid and Analogues", herein incorporated by reference. Equivalent products are described in said publication.

The residue (XIII) is prepared starting from lornoxicam, wherein the valence is saturated with H. It is prepared according to GB 2,003,877. Equivalent products are described in said patent.

The residue (LX) in group V is prepared from Sulindac, obtained according to US 3,654,349.


In general the connection between A and X_1 is, as seen, of ester or amidic type (NH or NR_{1c} , as defined in X) when R is of groups I, II, III, IV and V. For the formation of such connection all the synthesis routes well known for the formation of such bonds are usable.

The preparation of the compounds of formula $\text{A-X}_1\text{-N(O)}_2$ with the linking group X_1 of formula (B) is described in


published PCT application WO 00/51988 in the name of the Applicant, herein incorporated by reference.

The compounds of group A), as said, are effective in the incontinence treatment, they give lower side effects and are also parenterally administrable, therefore overcoming the drawbacks of the prior art mentioned in patent application WO 98/09948.


The drugs of the nitrate salts compounds B') are selected from B'1) anticholinergic drugs, B'2) calcium-antagonist drugs, B'3) drugs which facilitate the opening of the potassium channels, B'4) alpha-adrenergic agonistic drugs, B'5) alpha-adrenergic antagonist drugs, B'6) beta-adrenergic agonist drugs, B'7) antidepressant drugs, B'8) GABA agonist drugs, B'9) agonist drugs of the muscarinic receptor, and B'10) other drugs selected from inaperizone (B'10b), moxonidine (B'10c), papaverine (B'10e), benzydamine (B'10g):




(B'10b)



(B'10c)



(B'10e)






(B'10g)

B11) serotoninergetic antagonist drugs of the 5-HT₄ receptor.


In particular, compounds B') are selected from the following:

- B'1) propantheline (B'1a), emepronium (B'1b), trospium (B'1c), tolterodine (B'1d), darifenacin (B'1e), vamicamide (B'1f), zamifenacin (B'1g), atropine (B'1h), cycloidine (B'1i), oxybutynin (B'1l), N-desethyl-oxybutynin (B'1l-I), dicyclomine (B'1m), propiverine (B'1n), flavoxate (B'1o), terodiline (B'1p);
B'2) nifedipine (B'2a), flunarizine (B'2b), diltiazem (B'2c);
B'3) pinacidil;
B'4) ephedrine (B'4a), pseudoephedrine, phenylpropanolamine (B'4c), midodrine (B'4d), de-glymidodrine (B'4e);
B'5) alfuzosin (B'5a), doxazosin (B'5b), prazosin (B'5c);
B'6) clenbuterol (B'6a), terbutaline (B'6b), formoterol (B'6c);
B'7) imipramine (B'7a), clozapine (B'7b), milnacipran (B'7c), fluphenazine (B'7d), nortriptyline (B'7e), duloxetine (B'7f);
B'8) baclofen;
B'9) bethanechol;







(B'1c)




(B'1d)




(B'1f)




(B'1e)




(B'1h)




(B'1l)




(B'1g)




(B'1n)




(B'11-I)




(B'11i)




(B'1m)




(B'1o)




(B'1p)




(B'2a)




(B'2b)




(B'2c)




(B'3)




(B'4a)




(B'4c)




(B'4d)




(B'4e)




(B' 5a)




(B' 5b)




(B' 5c)




(B' 6a)




(B' 6b)




(B'6c)




(B'7a)




(B'7b)




(B'7c)




(B'7d)




(B'7e)



(B'7f)



(B'8)



(B'9)

B'11) 3-(piperidin-1-yl)propyl 4-amino-5-chloro-2-methoxybenzoate (B'11a), 1-[4-amino-5-chloro-2-(3,5-dimethoxyphenyl)methyl oxy]-3-[1-[2-methylsulphonylamino]ethyl piperidin-4-yl]-1-propanone (B'11b), 2(1-piperidinyl)ethyl-1H-indol-3-carboxylate (B'11c), (S)-2-chloro-5-methoxy-4-[5-(2-piperidylmethyl)-1,2,4-oxadiazol-3-yl]aniline (B'11d).

The synthesis of the compounds belonging to the classes B'1)-B'9) are described in the volume The Merck Index 12a Ed.; the synthesis of compound B'1e) is described in EP 388,054; of compound B'1g) is described in EP 350,309, of compound B'1d) is described in EP 325,571. The synthesis of compound B'11a) is carried out as described in EP 501,322, of compound B'11b) as described in Br. J. Pharmacol. 1995, 115. 1087-1095, of compound B'11c) as described in EP 429,984.

The compounds inhibiting the phosphodiesterase C) salifiable with organic or inorganic acids are selected from the following: (C1) 1-[4-ethoxy-3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazol[4,3-d]-pyrimidin-5-yl)-phenyl]sulphonyl]-4-methyl-piperazine (Sildenafil), (C2) 2-(2-propyloxyphenyl)-8-azapurin-6-one (Zaprinast), (C3) 2,6-bis-(diethanolamino)-4,8-dipiperidine pyrimido [5,4-d]-pyrimidine (dipyridamol), (C4) 6-chloro-4-(1,3-dioxaindan-5-yl) methylamino-2(4-carboxy-1-piperidinyl)-quinazoline, (C5) N-(phenylmethyl)-1-ethyl-1H-pyrazol-[3,4-b]-quinolin-4-amine, (C6) 1-(2-chlorobenzyl)-3-isobutyryl-2-propyl-6-aminocarbonyl-indol, (C7) 1-benzyl-6-chloro-2-[1-[3-(imidazol-1-yl)propyl]indol-5-yl-amino carbonyl]benzimidazol, (C8) 2-(1-imidazolyl)-5-(phenyl)-4-(1,3-dioxaindan-5-yl)methyl aminopyrimidine, (C9) 6-ethynyl-4-(2-methoxyethyl)amino-2-(1-imidazolyl)quinazoline, (C10) 1-cyclopentyl-3-ethyl-6-(2-propoxyphenyl)pyrazol[3,4-d]pyrimidin-4-one, (C11) 1-cyclopentyl-3-ethyl-6-(4-methoxybenzyl)-pyrazol-[3,4-d]-pyrimidin-4-one, (C12) 1,3-dimethyl-

6-(2-propoxy-5-methansulphonamidophenyl)-1,5-dihydro pyrazol[3,4-d]-pyrimidin-4-one, (C13) (6R, 12aR)-2,3, 6,7,12, 12a-hexahydro-2-methyl-6-(1,3-dioxan-5-yl)pyrazin [2',1':6,1] pyrido[3,4-b]indol-1,4-dione, (C14) 1-propyl-3-methyl-6-[2-propoxy-5-[(4'-methyl-1-pyrazinyl)sulphonamido] phenyl]-1,5-dihydropyrazol[3,4-d]pyrimidin-4-one, (C15) 3-(4-amino carboxyl-1-piperidinyl)-6-cyan-8-(3-chloro-4-methoxy-phthalazine, (C16) 2-(1-imidazolyl)-4-(1,3-dioxaindan-5-yl) methylamino-7,8-dihydro-5H-thiopyran[3,2-d]pyrimidine, (C17) 1-Cyclo pentyl-3-ethyl-6-(3-ethoxypyrid-4-yl)-1H-pyrazolo[3,4-d] pyrimidin-4-one, (C18) 1-[3-[1-[(4-Fluorophenyl)methyl]-7,8-dihydro-8-oxo-1H-imidazo[4,5-g]quinazolin-6-yl]-4-propoxyphenyl] carboxamide.

Examples of organic salts of C) are oxalate, tartrate, maleate, succinate, citrate, glycinate, lysinate; examples of inorganic anions are nitrate, chloride, sulphate, phosphate. Nitrate salts are preferred.

The above compounds inhibiting the phosphodiesterases are synthesized as described in the following references: (C1): G.B. 92,480; (C2): DE 2,162,096; (C3): The Merck Index 12th Ed.; (C4): WO 9422855; (C5): WO 9628159; (C6): WO 9632379; (C7): WO 9703070; (C8): USP 5,525,604; (C9): USP 5,436,233; (C10): WO 9628448; (C11): WO 9628429; (C12): EP 636,626; (C13): WO 9519978; (C14): EP 636,626; (C15): WO 9605176; (C16): EP 728,759; (C17): US 5,294,612; (C18): J. Med. Chem 2000 43 1257-1263.

The nitrate salts of compounds B') and of compounds C) can be prepared as for example described in patent application WO 99/45004 in the name of the Applicant; the other salts of compounds C) with anions different from nitrate are prepared by methods known in the prior art, such as for example described in patent application WO 96/28448.

For the use according to the present invention one or more salts of the drugs of classes A)-C) are formulated in the corresponding pharmaceutical formulations according to well known techniques in the art, together with the usual excipients. The formulations can be for oral, parenteral use and are prepared as known in the prior art. See for example the volume "Remington's Pharmaceutical Sciences 15th Ed."

The dosages of the salts of the invention in their pharmaceutical compositions are the same, and generally lower

than those of their precursors of the above mentioned classes, said salts generally being more effective and better tolerated.

The following Examples illustrate but do not limit the scope of the invention.

EXAMPLE 1

Preparation of oxybutynin nitrate salt (B11)

To a solution of oxybutynin chloride (1.1 g, 2.82 mmoles) (B'11) in acetonitrile (25 ml) silver nitrate (0.48 g, 2.82 mmoles) dissolved in acetonitrile (10 ml) is added. The mixture is maintained under stirring for 30 minutes sheltered from light and at room temperature. The precipitate (AgCl) is filtered and the solution is concentrated under reduced pressure up to half of the initial volume. Ethyl ether (50 ml) is added. By cooling with ice a precipitate is separated which is filtered and washed with ethyl ether (3 X 5 ml). After drying 0.8 g of oxybutynin nitrate salt are obtained as an amorphous solid. Yield 68%.

Melting point 86-87°C.

Elementary analysis

Calculated %:	C 62.84	H 7.67	N 6.66
Found %:	C 62.67	H 7.66	N 6.70

EXAMPLE 2

Preparation of benzidamine nitrate salt (B'10g)

1) Preparation of benzidamine base

Benzidamine hydrochloride (3 g, 8.7 mmoles) (B'10g) is dissolved in an aqueous solution of sodium hydroxide (10% w/w, 45 ml) and the solution is extracted with ethyl acetate (3 X 50 ml). The joined organic phases are washed with water, anhydriified with sodium sulphate and the solvent evaporated under reduced pressure. An yellow oil formed by benzidamine free base is obtained.

¹H NMR (DMSO): 7.65-7.6 (2H, m); 7.45-7.2 (6H, m); 7.15 (1H, t); 5.45 (2H, s); 4.4 (2h, t); 2.4 (2H, t); 2.2 (6H, s); 2.0 (2H, m).

2) Preparation of benzidamine nitrate salt

To a solution of benzidamine (2.5 g, 8.1 mmoles) in acetonitrile (15 ml), cooled at 0 °C, nitric acid 65% (0.560 ml, 8.1 mmoles) is added. The mixture is maintained under stirring at 0°C for 30 minutes, the temperature is let reach the room temperature and the mixture is maintained under

stirring for 1 hour. After addition of ethyl ether (10 ml) a white solid is separated which is filtered and washed with ethyl ether. After drying 2.6 g of benzidamine nitrate salt are obtained. Melting point 143-144°C.

Elementary analysis

Calculated %:	C	61.29	H	6.49	N	15.04
Found %:	C	60.93	H	6.45	N	14.97

EXAMPLE 3

Preparation of papaverine nitrate salt (B'10e)

1) Preparation papaverine base

Papaverine hydrochloride (3 g, 8 mmoles) (B'10e) is dissolved in an aqueous solution of sodium hydroxide (10% w/w, 50 ml) and the solution is extracted with chloroform (3 X 50 ml). The joined organic phases are washed with water, anhydriified with sodium sulphate and the organic solvent evaporated under reduced pressure. Papaverine base (2.7 g) is obtained as an amorphous solid.

¹H NMR (DMSO): 8.4 (1H, d); 7.6 (2H, d); 7.4 (1H, s); 6.8 (2H, m); 4.5 (2H, s); 3.9 (6H, d); 3.7 (6H, d).

2) Preparation of papaverine nitrate salt

To a solution of papaverine (2.6 g, 7.6 mmoles) in acetonitrile (100 ml), cooled at 0 °C, nitric acid 65% (0.560 ml, 8.1 mmoles) is added. The mixture is maintained under stirring at 0°C for 30 minutes, it is let reach the room temperature and the mixture is maintained under stirring for 2 hours. The formed precipitate is filtered and washed with acetonitrile. After drying 2.3 g of papaverine nitrate salt are obtained.

Elementary analysis

Calculated %:	C	59.69	H	5.51	N	6.96
Found %:	C	58.68	H	5.38	N	6.86

EXAMPLE 4

Preparation of phenylpropanolamine nitrate salt (B'4c)

To a solution of phenylpropanolamine hydrochloride (2 g, 10.75 mmoles) (B'4c) in acetonitrile (50 ml) silver nitrate (1.83 g, 10.77 mmoles) is added. The salt preparation is carried out following the procedure described in Example 1. The phenylpropanolamine nitrate salt is obtained as an amorphous solid.

Elementary analysis

Calculated %:	C	50.46	H	6.59	N	13.08
Found %:	C	50.60	H	6.62	N	13.12

EXAMPLE 5

Preparation of pinacidil nitrate salt (B'3)

To a solution of pinacidil (3 g, 12.23 mmol) (B'3) in acetonitrile (100 ml), cooled at 0°C, nitric acid 65% (0.850 ml, 12.27 mmol) is added. The mixture is maintained under stirring at 0°C for 30 minutes. At the end it is let reach the room temperature and the mixture is maintained under stirring for 2 hours. After addition of ethyl ether a precipitate forms which is filtered and washed with ethyl ether (3 X 20 ml). After drying 2.3 g of pinacidil nitrate salt are obtained. Yield 60%.

Elementary analysis

Calculated %:	C	50.64	H	6.54	N	27.26
Found %:	C	50.73	H	6.62	N	27.19

EXAMPLE 6

Preparation of terodiline nitrate salt (B'1p)

Terodiline hydrochloride (2 g, 6.3 mmol) (B'1p) is dissolved in an aqueous solution of sodium hydroxide (10% w/w, 35 ml) and the solution extracted with ethyl acetate (3 X 50 ml). The joined organic phases are washed with water, anhydried with sodium sulphate and the organic solvent evaporated under reduced pressure. The residue is dissolved in acetonitrile (15 ml) and the solution is cooled at 0°C. Nitric acid 65% (0.440 ml, 6.35 mmol) is added. The mixture is maintained under stirring at 0°C for 30 minutes, then it is let reach the room temperature and the mixture is maintained under stirring for 1 hour. By adding ethyl ether (10 ml) a white solid is separated which is filtered and washed with ethyl ether. After drying 1.2 g of terodiline nitrate salt are obtained. Yield 55%.

Elementary analysis

Calculated %:	C	69.74	H	8.19	N	8.13
Found %:	C	69.80	H	8.25	N	8.09

EXAMPLE 7

Preparation of propantheline nitrate salt (B'1a)

The compound is prepared starting from a solution of propantheline bromide (3 g, 6.7 mmol) (B'1a) in acetonitrile (80 ml), adding silver nitrate (1.3 g, 7.06 mmol)

dissolved in acetonitrile (10 ml), and following the procedure described in Example 1. After drying, propantheline nitrate salt is obtained as an amorphous solid (1.4 g). Yield 48%.

Elementary analysis

Calculated %:	C 64.02	H 7.24	N 6.49
Found %:	C 64.11	H 7.27	N 6.45

EXAMPLE 8

Preparation of flavoxate nitrate salt (B'1o)

The compound is prepared starting from a solution of flavoxate hydrochloride (2 g, 4.7 mmoles) (B'1o) in acetonitrile (50 ml) adding a silver nitrate solution (0.800 g, 4.76 mmoles) in acetonitrile (10 ml) and following the procedure described in Example 1. After drying flavoxate nitrate salt is obtained as an amorphous solid (1.1 g). Yield 50%.

Elementary analysis

Calculated %:	C 63.42	H 5.77	N 6.16
Found %:	C 63.52	H 5.98	N 6.20

EXAMPLE 9

Preparation of dicyclomine nitrate salt (B'1m)

The compound is prepared starting from a solution of dicyclomine hydrochloride (2 g, 5.78 mmoles) (B'1m) in acetonitrile (50 ml) adding silver nitrate (0.990 g, 4.76 mmoles) dissolved in acetonitrile (10 ml) and following the procedure described in Example 1. After drying dicyclomine nitrate salt is obtained as an amorphous solid (1.3 g). Yield 60%.

Elementary analysis

Calculated %:	C 61.26	H 9.74	N 7.52
Found %:	C 61.19	H 9.69	N 7.58

PHARMACOLOGICAL EXAMPLES

The activity in the urinary incontinence of the compounds according to the present invention has been evaluated in an experimental model of inhibition of the bladder contraction.

The degree of the relaxation induced in the urinary bladder is a measure of the inhibitory action of the urinary incontinence of the drugs described in the present application.

Guinea-pigs of male sex having an average weight equal to 300-500 g were sacrificed and bled. The urinary bladder was removed and prepared for determining the myorelaxing activity in vitro, according to the method described by L.Nilvenbrant, Eur.J.Pharmacol. 327,195-207, 1997.

The obtained tissue strips were contracted with carbachol 10^{-6} M in physiological solution and the relaxation was determined in the presence of the compounds indicated in Table 1 at the concentrations mentioned therein. The 2-(acetyloxy) benzoic acid 6-(nitroxymethyl)-2-methylpyridyl ester hydrochloride was prepared according to Example 1 of patent application PCT/EP 00/01454 (NCX 4050).

The sildenafil nitrate salt was prepared as described in patent application WO 99/67231 (Ex. 3).

In Table 1 the results are expressed as a percentage of the maximum inhibition of the contractions induced by carbachol 10^{-6} M and they show that the compounds of the present invention are active in the urinary incontinence since they are able to exert a significant relaxing effect on the urinary guinea-pig bladder, which in the case of the nitrate salts of the drugs used in the incontinence is higher than that of the precursors.


Table 1

Activity in the urinary incontinence of the compounds NCX 4050, sildenafil nitrate, sildenafil citrate, oxybutynin nitrate and oxybutynin hydrochloride in an experimental model in vitro of strips of urinary guinea-pig bladder contracted with carbacol		
Treatment	Concentration (M)	Urinary bladder contraction %
Placebo	-----	100
NCX 4050	3×10^{-5}	71
Sildenafil Nitrate	3×10^{-5}	31
Sildenafil Citrate	3×10^{-5}	52
Oxybutynin Hydrochloride (Comp)	10^{-6}	30
Oxybutynin Nitrate	10^{-6}	0

CLAIMS

1. Use in the incontinence of one or more of the following classes of drugs selected from the following:

A) nitric oxide donor drugs, salified and non salified of formula



wherein A, X_1 , Z have the meaning defined below;

B') nitrate salts of drugs used for the incontinence and which do not contain in the molecule a nitric oxide donor group;

C) organic or inorganic salts of compounds inhibiting phosphodiesterases;

in the compounds of general formula:




z is an integer and is 1 or 2, preferably 2;

A = $R(COX_u)_t$ and wherein t is an integer 0 or 1; u is 0 or 1;

X = O, NH, NR_{1c} wherein R_{1c} is a linear or branched C_1 - C_{10} alkyl;

X_1 is the following bivalent linking group:



wherein:

nIX is an integer in the range 0-3;


nIIX is an integer in the range 1-3;

R_{TIX} , $R_{TIX'}$, R_{TIIIX} , $R_{TIIIX'}$, equal to or different from each other are H or a linear or branched C_1 - C_4 alkyl;


Y is a heterocyclic ring containing one or two nitrogen atoms, optionally one oxygen or sulphur atom, said saturated, unsaturated or aromatic ring having 5 or 6 atoms;

R of the radical A of formula $A - X_1 - N(O)_z$ is selected from the following groups:

Group I) wherein $t = 1$ and $u = 1$
Ia)



Ib)



wherein:


R_1 is the $OCOR_3$ group; wherein R_3 is methyl, ethyl or a linear or branched C_3 - C_5 alkyl, or the residue of a heterocycle having only one ring having 5 or 6 atoms which can be aromatic, partially or totally hydrogenated, containing one or more heteroatoms independently selected from O, N and S;

R_2 is hydrogen, hydroxy, halogen, linear or branched C_1 - C_4 alkyl, linear or branched C_1 - C_4 alkoxy; a linear or branched C_1 - C_4 perfluoroalkyl, for example trifluoromethyl; nitro, amino, mono- or di- (C_{1-4}) alkylamino;


nI is an integer 0 or 1;

group II) wherein $t = 1$, $u = 1$

IIa)



IIb)




wherein:

R_{II5} is H, linear or branched when possible C_1-C_3 alkyl;
 R_{II6} has the same meaning as R_{II5} , or when R_{II5} is H it can be benzyl;

R_{II1} , R_{II2} and R_{II3} can independently be hydrogen, linear or branched when possible C_1-C_6 alkyl, or linear or branched when possible C_1-C_6 alkoxy, or Cl, F, Br;

R_{II4} is R_{II1} or bromine;


IIb) is the residue of the 2-[(2-methyl-3-(trifluoromethyl)phenyl)amino]-3-pyridincarboxylic acid and when the -COOH group is present the compound is known as flunixin; group III) wherein $t = 1$, $u = 1$ and R is




wherein:

R_{2a} and R_{3a} are H, linear or branched when possible, substituted or not, C_1-C_{12} alkyl or allyl, with the proviso that if one of the two is allyl the other is H; preferably R_{2a} is H, C_1-C_4 alkyl, R_{3a} is H;


R_{1a} is selected from




(II)




(XXI)




(IV)




(XXXV)




(VI)




(VII)




(VIII)



(IX)




(X)




(III)


IIID) R_{1a} corresponds to the following formulas:




(IIIa)




(XXX)




(XXXI)




(XXXII)




(XXXIII)



(XXXVI)



(XXXVII)



(XII)

wherein the meanings are the following:

- when R_{1a} is as defined in formula (IV), Ketoprofen residue: R_{III1} is H, SR_{III3} wherein R_{III3} contains from 1 to 4 carbon atoms, linear or branched when possible; R_{III2} is H, hydroxy;
- when R_{1a} is as defined in formula (XXI), carprofen residue: R_{xdi0} is H, linear or branched when possible alkyl from 1 to 6 carbon atoms, C_1-C_6 alkoxycarbonyl linked to a C_1-C_6 alkyl, C_1-C_6 carboxyalkyl, C_1-C_6

alkanoyl, optionally substituted with halogens, benzyl or halobenzyl, benzoyl or halobenzoyl;

R_{xxi} is H, halogen, hydroxy, CN, C_1-C_6 alkyl optionally containing OH groups, C_1-C_6 alkoxy, acetyl, benzyloxy, SR_{xxi2} wherein R_{xxi2} is C_1-C_6 alkyl; C_1-C_3 perfluoroalkyl; C_1-C_6 carboxyalkyl optionally containing OH groups, NO_2 , amino; sulphamoyl, di-alkyl sulphamoyl with C_1-C_6 alkyl, or difluoroalkylsulphonyl with C_1-C_3 alkyl;

R_{xxii} is halogen, CN, C_1-C_6 alkyl containing one or more OH groups, C_1-C_6 alkoxy, acetyl, acetamido, benzyloxy, SR_{III3} being R_{III3} as above defined, C_1-C_3 perfluoroalkyl, hydroxy, C_1-C_6 carboxyalkyl, NO_2 , amino, mono- or di-alkyl-amino C_1-C_6 ; sulphamoyl, di-alkyl sulphamoyl C_1-C_6 , or di-fluoroalkylsulphamoyl as above defined; or R_{xxi} together with R_{xxii} is a C_1-C_6 alkylene dioxy;


- when R_{1a} is as defined in formula (XXXV) tiaprofenic acid residue:

Ar is phenyl, hydroxyphenyl optionally mono or polysubstituted with halogen, alkanoyl and alkoxy C_1-C_6 , C_1-C_6 , preferably C_1-C_3 , trialkyl, cyclopentyl, cyclohexyl, cycloheptyl, heteroaryl, preferably thienyl, furyl optionally containing OH, pyridyl;

- when R_{1a} is as defined in formula (II), suprofen residue, wherein R_{3a} is H, R_{2a} is methyl and $X = O$;
- when R_{1a} is as defined in formula (VI), R is the residue of indoprofen when $R_{2a} = H$ and $R_{3a} = CH_3$; of indobufen when R_{2a} is equal to H and $R_{3a} = C_2H_5$; $X = O$;
- when R_{1a} is as defined in formula (VIII), R is the e-todolac residue when $R_{2a} = R_{3a} = H$ and $X = O$;
- when R_{1a} is as defined in formula (VII), R is the fenoprofen residue when $R_{3a} = H$, $R_{2a} = CH_3$ and $X = O$;
- when R_{1a} is as defined in formula (III), R is the fenbufen residue when $R_{2a} = R_{3a} = H$ and $X = O$;
- when R_{1a} is as defined in formula (IX), R is the flurbiprofen residue when $R_{3a} = H$, $R_{2a} = CH_3$, $X = O$;

- when R_{1a} is as defined in formula (X) R is the tolmetin residue when $R_{2a} = R_{3a} = H$, $X = O$;
- in group IIID) R_{1a} corresponds to the following formulas:
 - IIIa), when $R_{2a} = H$ and $R_{3a} = CH_3$, the pranoprofen residue is obtained: α -methyl-5H-[1]benzopyran-[2,3-b]pyridin-7-acetic acid; the preferred compound has $R_{2a} = H$, $R_{3a} = CH_3$, $u = 1$ and $X = O$;
 - (XXX), when $R_{2a} = H$ and $R_{3a} = CH_3$, the bermoprofen residue is obtained: dibenz[b,f]oxepin-2-acetic acid;
 - (XXXI), when $R_{2a} = H$ and $R_{3a} = CH_3$, R is the radical of the CS-670 compound: 2-[4-(2-oxo-1-cyclohexyliden methyl) phenyl]propionic acid;
 - (XXXII), when $R_{2a} = R_{3a} = H$ the Pemedolac residue is obtained;
 - (XXXIII), when $R_{2a} = R_{3a} = H$ the pyrazolac residue is obtained: 4-(4-chlorophenyl)-1-(4-fluoro phenyl)-3-pyrazolic acid;
 - (XXXVI), when $R_{2a} = H$, $R_{3a} = CH_3$, the zaltoprofen residue is obtained; when the residue is saturated with an hydroxyl or amino group, or with the carboxylic function the compounds are known as dibenzothiepine derivatives;
 - (XXXVII), when $R_{2a} = R_{3a} = H$ the mofezolac residue is obtained: 3,4-di(p-methoxyphenyl)isoxazol-5-acetic acid;
 - (XII), when $R_{2a} = R_{3a} = H$ the bromfenac residue is obtained: 2-amino-3-(4-bromobenzoyl)benzeneacetic acid;

in group IV) wherein $t = 1$, $u = 1$, R is




wherein:


R_{IVd} and R_{IVd1} are at least one H and the other a linear or branched C_1 - C_6 , preferably C_1 and C_2 alkyl, or difluoroalkyl with the alkyl from 1 to 6 carbon atoms, C_1 is

preferred, or R_{IVd} and R_{IVd1} form together a methylene group;


R_{IV} has the following meaning:



(II)



(X)



(III)

wherein the compounds of group IV) have the following meanings:

- in formula (II):


R_{IV-ii} is C_1-C_6 alkyl, C_3-C_7 cycloalkyl, C_1-C_7 alkoxyethyl, C_1-C_3 trifluoroalkyl, vinyl, ethynyl, halogen, C_1-C_6 alkoxy, difluoroalkoxy, with the C_1-C_7 alkyl, C_1-C_7 alkoxyethyl, alkylthio methoxy with the C_1-C_7 alkyl, alkyl methylthio with the C_1-C_7 alkyl, cyan, difluoromethylthio, phenyl- or phenylalkyl substituted with C_1-C_8 alkyl.

- formula (X) loxoprofen residue;


- in formula (III):

R_{IV-iii} is a C_2-C_5 alkyl, optionally branched when possible, C_2 and C_3 alkoxy, allyloxy, phenoxy, phenylthio, cycloalkyl from 5 to 7 carbon atoms, optionally substituted in position 1 by a C_1-C_2 alkyl;


Group V)




(VII)




(IX)




(IV)




(V)



(III)




(II)




(LX)


Group VE)




(X)




(XI)



(XIII)



(XXXX)






(XXXXI)

In group V):

- when R is formula (II), R_{VII} is H or a linear or branched C_1 - C_4 alkyl;
 R_{VII-1} is R_{VII} , or a linear or branched C_1 - C_4 alkoxy; Cl, F, Br; the position of R_{VII-1} being ortho, or metha, or para;
- when R is formula (V),
 of which the residue of the known tenidap has been indicated;
- when R is formula (V) $A = R$ and $t = 0$,
- when R is formula (VII), A is RCO, $t = 1$ $u = 0$ or A is R and $t = 0$;
- when R is formula (IX), $A = R$ and $t = 0$, or $A = RCO$ with $t = 1$ and $u = 0$;

- when R is formula (III) $A = \text{RCOO}$, $t = 1$ and $u = 0$ or 1; or $t = 0$ and $A = R$;
 - when R is formula (IV) $A = \text{RCOO}$, $t = 1$ and $u = 1$;
 - when R is formula (LX) and in $(\text{COX}_u)_t$, $u = t = 1$ and X is oxygen, the precursor compound is sulindac;
 - when R is formula (X) it is the meloxicam residue;
 - when R is formula (XI) the residue is known as ampiroxicam when the termination is $-\text{CH}(\text{CH}_3)\text{OCOC}_2\text{H}_5$;
 - when R is formula (XIII) and the valence is saturated with H, the residue derives from lornoxicam;
 - when R is formula (XXXX) and the valence is saturated with H the compound is known as paracetamol;
 - when R is formula (XXXXI) and the valence is saturated with H the compound is known as tramadol.
2. Use according to claim 1, wherein Y is selected from the following:



3. Use according to claim 2, wherein Y is Y12 (pyridyl) substituted in position 2 and 6.
4. Use according to claims 1-3, wherein in the compounds A) of formula $A-X_1-N(O)_z$, z is 2 and nIX and nIIX in formula

(B) of X_1 are integers equal to 1 and R_{TIX} , $R_{TIX'}$, R_{TIIIX} , $R_{TIIIX'}$ are equal to H.


5. Use according to claims 1-4, wherein in the compounds of formula A) $A-X_1-N(O)_z$, R, X, u and t of formula A = $R(COX_u)_t$, and Y in formula (B) of X_1 , have the following meanings:

- when R is selected from group I), in the compounds of formula Ia) X is equal to O or NH, R_1 is acetoxy, preferably in ortho position with respect to -CO-, R_2 is hydrogen; in X_1 $R_{TIX} = R_{TIX'} = R_{TIIIX} = R_{TIIIX'} = H$, $n_{IX} = n_{IIX} = 1$ and Y is an aromatic ring having 6 atoms, containing one nitrogen atom, said aromatic ring having the two free valences in position 2 and 6; in the compounds of formula Ib) $R_3 = CH_3$, $nI = 0$, X is equal to O, X_1 is as above defined for Ia); in this case Ib) is the residue of the acetylsalicylsalicylic acid;
- when R is selected in group II) in formula IIa) R_{II1} , R_{II4} are hydrogen and R_{II2} and R_{II3} are chlorine in ortho position with respect to NH; R_{II5} and R_{II6} are H, X is equal to O, and X_1 is as above defined for the compounds of formula Ia);
- when R is selected in group III),
- when R_{1a} is as defined in formula (IV) R_{III1} and R_{III2} are H, R_{3a} is H, and R_{2a} is methyl, $X = O$;
- when R_{1a} is as defined in formula (XXI) R_{XXI0} is H, the linking group is in position 2, R_{XXI1} is H, R_{XXI1} is chlorine and it is in para position with respect to nitrogen;
- when R_{1a} is as defined in formula (XXXV) Ar is phenyl, R_{3a} is H, R_{2a} is methyl and X is O; R_{3a} is H, R_{2a} is methyl and X is O;
- when R_{1a} is as defined in formula IIIa), $R_{2a} = H$, $R_{3a} = CH_3$, $u = 1$ and $X = O$;
- when R_{1a} is as defined in formula (XXX) $R_{2a} = H$, $R_{3a} = CH_3$, $u = 1$ and $X = O$;
- when R_{1a} is as defined in formula (XXXI), $R_{2a} = H$, $R_{3a} = CH_3$, $u = 1$ and $X = O$;
- when R_{1a} is as defined in formula (XXXII), $R_{2a} = R_{3a} = H$, $u = 1$ and $X = O$;

- when R_{1a} is as defined in formula (XXXIII), $R_{2a} = R_{3a} = H$, $u = 1$ and $X = O$;
- when R_{1a} is as defined in formula (XXXVI), $R_{2a} = H$, $R_{3a} = CH_3$, $u = 1$ and $X = O$;
- when R_{1a} is as defined in formula (XXXVII), $R_{2a} = R_{3a} = H$, $t = 1$ and $X = O$;
- when R_{1a} is as defined in formula (XII), $R_{2a} = R_{3a} = H$, $u = 1$, $t = 1$, $X = O$, $R_{2a} = R_{3a} = H$; or $t = 0$;

when R is selected in group IV),

- when R_{IV} is the formula (II), $R_{IV-ii} = CH_3O-$, $R_{IVd} = H$ and $R_{IVd1} = CH_3$, $X = O$ and X_1 is as above defined for Ia);
- when R_{IV} is formula (X), $R_{IVd} = H$, $R_{IVd1} = CH_3$, $X = O$ and X_1 is as above defined for Ia);
- when R_{IV} is formula (III), R_{IV-iii} is




and $R_{IVd} = H$, R_{IVd1} is CH_3 , $X = O$ and X_1 is as above defined for Ia);

when R is selected in group V,


- when R is formula (II), R_{vii} and R_{vii-1} are H , and $A = R$;
- when R is formula (X), $A = RCO$, $t = 1$ and $u = 0$;
- when R is formula (XI), $A = RCO$, $t = 1$ and $u = 0$;
- when R is formula (XIII), $A = RCO$, $t = 1$ and $u = 0$;
- when R corresponds to formula (XXXX) or (XXXXI), $A = RCO$, $t = 1$ and $u = 0$.

6. Use according to claims 1-5, wherein the drugs of the nitrate salts compounds B') are selected from B'1) anticholinergic drugs, B'2) calcium antagonist drugs, B'3) drugs which facilitate the opening of the potassium channels, B'4) alpha-adrenergic agonist drugs, B'5) alpha-adrenergic antagonist drugs, B'6) beta-adrenergic agonist drugs, B'7) antidepressant drugs, B'8) GABA agonist drugs, B'9) agonist drugs of the muscarinic receptor and B'10) other drugs selected from inaperizone (B'10b), moxonidine (B'10c), papaverine (B'10e),


benzylamine (B'10g)




(B'10b)



(B'10c)



(B'10e)




(B'10g)

B11) antagonist serotonergic drugs of the 5-HT₄ receptor.


7. Use according to claim 6, wherein the compounds B') are selected from the following:

B'1) propantheline (B'1a), emepronium (B'1b), trospium (B'1c), tolterodine (B'1d), darifenacin (B'1e), vamicamide (B'1f), zamifenacin (B'1g), atropine (B'1h), cyclo-drine (B'1i), oxybutynin (B'1l), N-desethyl-oxybutynin (B'1l-I), dicyclomine (B'1m),


- propiverine (B'1n), flavoxate (B'1o), terodiline (B'1p);
- B'2) nifedipine (B'2a), flunarizine (B'2b), diltiazem (B'2c);
- B'3) pinacidil;
- B'4) ephedrine (B'4a), pseudoephedrine, phenylpropanolamine (B'4c), midodrine (B'4d), de-glymidodrine (B'4e);
- B'5) alfuzosin (B'5a), doxazosin (B'5b), prazosin (B'5c)
- B'6) clenbuterol (B'6a), terbutaline (B'6b), formoterol (B'6c);
- B'7) imipramine (B'7a), clozapine (B'7b), milnacipran (B'7c), fluphenazine (B'7d), nortriptyline (B'7e), duloxetine (B'7f);
- B'8) baclofen;
- B'9) bethanechol;




(B'1a)




(B'1b)




(B'1c)



(B'1d)




(B'1e)




(B'1f)


(B'1h)




(B'11)




(B'1g)




(B'1n)




(B'11-I)




(B'1i)




(B'1m)




(B'1o)




(B'1p)




(B'2a)




(B'2b)




(B' 2c)




(B' 3)




(B' 4a)




(B' 4c)




(B' 4d)




(B' 4e)




(B' 5a)




(B' 5b)




(B' 5c)




(B' 6a)




(B' 6b)




(B' 6c)




(B' 7a)




(B' 7b)




(B'7c)




(B'7d)




(B'7e)



(B'7f)



(B'8)



(B'9)

B'11) 3-(piperidin-1-yl)propyl 4-amino-5-chloro-2-methoxy benzoate (B'11a), 1-[4-amino-5-chloro-2-(3,5-dimethoxy phenyl)methyl oxy]-3-[1-[2-methylsulphonylamino]ethyl piperidin-4-yl]-1-propanone (B'11b) 1-piperidinylethyl-1H-indol-3-carboxylate (B'11c), (S)-2-chloro-5-methoxy-4-[5-(2-piperidylmethyl)-1,2,4-oxadiazol-3-yl] aniline (B'11d).

8. Use according to claims 1-7, wherein the compounds inhibiting the phosphodiesterase C) salifiable with organic or inorganic acids are selected from the following: (C1) 1-[4-ethoxy-3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazol[4,3-d]-pyrimidin-5-yl)-phenyl]sulphoyl]-4-methyl-piperazine (Sildenafil), (C2) 2-(2-propyloxyphenyl)-8-azapurin-6-one (Zaprinst), (C3) 2,6-bis-(diethanolamino)-4,8-dipiperidino pyrimido [5,4-d]-pyrimidine (dipyridamol), (C4) 6-chloro-4-(1,3-dioxain-

dan-5-yl)methylamino-2(4-carboxy-1-piperidinyl)-quinazoline, (C5) N-(phenylmethyl)-1-ethyl-1H-pyrazol-[3,4-b]-quinolin-4-amine, (C6) 1-(2-chlorobenzyl)-3-isobutyryl-2-propyl-6-aminocarbonyl-indol, (C7) 1-benzyl-6-chloro-2-[1-[3-(imidazol-1-yl)propyl]indol-5-yl-amino carbonyl]benzimidazol, (C8) 2-(1-imidazolyl)-5-(phenyl)-4-(1,3-dioxaindan-5-yl)methyl aminopyrimidine, (C9) 6-ethynyl-4-(2-methoxyethyl)amino-2-(1-imidazolyl) quinazoline, (C10) 1-cyclopentyl-3-ethyl-6-(2-propoxy-phenyl)pyrazol[3,4-d]pyrimidin-4-one, (C11) 1-cyclopentyl-3-ethyl-6-(4-methoxybenzyl)-pyrazol-[3,4-d]-pyrimidin-4-one, (C12) 1,3-dimethyl-6-(2-propoxy-5-methansulphonamidophenyl)-1,5-dihydro pyrazol[3,4-d]-pyrimidin-4-one, (C13) (6R, 12aR)-2,3, 6,7,12, 12a-hexahydro-2-methyl-6-(1,3-dioxan-5-yl)pyrazino [2',1':6,1] pyrido[3,4-b]indol-1,4-dione, (C14) 1-propyl-3-methyl-6-[2-propoxy-5-[(4'-methyl-1-pyrazinyl) sulphonamido] phenyl]-1,5-dihydropyrazol[3,4-d]pyrimidin-4-one, (C15) 3-(4-amino carbonyl-1-piperidinyl)-6-cyan-8-(3-chloro-4-methoxy-phthalazine, (C16) 2-(1-imidazolyl)-4-(1,3-dioxaindan-5-yl) methylamino-7,8-dihydro-5H-thiopyran[3,2-d]pyrimidine (C17) 1-Cyclopentyl-3-ethyl-6-(3-ethoxypyrid-4-yl)-1H-pyrazolo[3,4-d] pyrimidin-4-one, (C18) 1-[3-[1-[(4-Fluorophenyl)methyl]-7,8-dihydro-8-oxo-1H-imidazo[4,5-g]quinazolin-6-yl]-4-propoxyphenyl] carboxamide.

9. Use according to claim 8, wherein the organic salts of C) are selected from oxalate, tartrate, maleate, succinate, citrate, glycinate, lysinate; and the inorganic anions are selected from nitrate, chloride, sulphate, phosphate.
10. Use according to claims 8-9, wherein the preferred anion is nitrate.
11. Use according to claims 1-10, obtained with formulations by oral, parenteral use containing one or more salts of the drugs of classes A)-C).
12. Nitrate salts of drugs compounds B') of claims 1, 6 and 7, excluding the nitrate salts respectively of nifedipine, flunarizine, diltiazem.
13. Nitrate salts of drugs compounds C) of claims 1, 8 and 9 excluding sildenafil nitrate, zaprinast nitrate and dipyridamol nitrate.

14. Formulations according to claim 11.
15. Nitrate salts according to claims 12-13 for use as a medicament.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
14 February 2002 (14.02.2002)

PCT

(10) International Publication Number
WO 02/011707 A3

(51) International Patent Classification⁷: **A61K 31/04**,
A61P 13/00, A61K 31/216, 31/416, 31/472, 31/137,
31/4409, 31/352, 31/44, 31/519, 31/453, 31/215

(74) Agents: **SAMA, Daniele** et al.; Sama Patents, Via G.B.
Morgagni 2, I-20129 Milano (IT).

(21) International Application Number: PCT/EP01/08734

(81) Designated States (*national*): AE, AG, AL, AU, BA, BB,
BG, BR, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE,
HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV,
MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK,
TR, TT, UA, US, UZ, VN, YU, ZA.

(22) International Filing Date: 27 July 2001 (27.07.2001)

(25) Filing Language: English

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).

(26) Publication Language: English

(30) Priority Data:
MI2000A 001848 8 August 2000 (08.08.2000) IT

(71) Applicant (*for all designated States except US*): **NICOX**
S.A. [FR/FR]; 1900, rue des Crêtes, F-06560 Sophia An-
tipolis (FR).

Published:
— with international search report

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **DEL SOLDATO**,
Piero [IT/IT]; Via Toti, 22, I-20052 Monza (IT). **BENE-**
DINI, Francesca [IT/IT]; Via Padova, 286, I-20100 Mi-
lano (IT).

(88) Date of publication of the international search report:
5 December 2002

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: DRUGS FOR INCONTINENCE

(57) Abstract: Use in the incontinence of one or more of the following classes of drugs selected from the following: B) salified and non salified nitric oxide-donor drugs, of formula: A - X₁ - N(O)₂, B') nitrate salts of drugs used for the incontinence, and which do not contain in the molecule a nitric oxide donor group; C) organic or inorganic salts of compounds inhibiting phosphodiesterases.

International Application No
PCT/EP 01/08734

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

Int. Application No
PCT/EP 01/08734

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/04 A61P13/00 A61K31/216 A61K31/416 A61K31/472
A61K31/137 A61K31/4409 A61K31/352 A61K31/44 A61K31/519
A61K31/453 A61K31/215

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, CHEM ABS Data, MEDLINE, EMBASE, PASCAL

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 09948 A (NICOX SA ;DEL SOLDATO PIERO (IT); SANNICOLA FRANCESCO (IT)) 12 March 1998 (1998-03-12) cited in the application * see in particular p. 45, l. 10 - p. 47, l. 7; claim 1 *	12,14,15
X	WO 96 37202 A (ALZA CORP) 28 November 1996 (1996-11-28) * see in particular p. 3, l. 22-24; p. 5, l. 8-11; claim 2 *	12,14,15



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
 "E" earlier document but published on or after the international filing date
 "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
 "O" document referring to an oral disclosure, use, exhibition or other means
 "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
 "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
 "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
 "&" document member of the same patent family

Date of the actual completion of the international search

22 July 2002

Date of mailing of the international search report

02.09.02

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Rodriguez-Palmero, M

INTERNATIONAL SEARCH REPORT

.....national application No.
PCT/EP 01/08734

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 1-11
because they relate to subject matter not required to be searched by this Authority, namely:
The present claims 1-11 concern subject-matter considered by this Authority to be covered by the provisions of Rule 39.1(iv) PCT and have therefore not been searched.
2. ☒ Claims Nos.: 12-15 (all of them partially)
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

As a result of the prior review under R. 40.2(e) PCT,
no additional fees are to be refunded.

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☒ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

In ☐ International Application No
PCT/EP 01/08734

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 436 233 A (LEE SUNG J ET AL) 25 July 1995 (1995-07-25) * see in particular column 18, table 1 and column 80, example 18 *	14
X	WO 96 28448 A (SANOFI WINTHROP INC) 19 September 1996 (1996-09-19) * see in particular p. 12, l. 4-35; p. 17, example 6 *	14
X	EP 0 943 613 A (KYOWA HAKKO KOGYO KK) 22 September 1999 (1999-09-22) * see in particular p. 3, paragraph 1; p. 5, paragraph 22 *	13
P, X	WO 00 51988 A (NICOX SA ; DEL SOLDATO PIERO (IT); BENEDINI FRANCESCA (IT)) 8 September 2000 (2000-09-08) * see in particular examples 1-8, 13 and 14 *	14
A	SULLIVAN J ET AL: "Pharmacological management of incontinence." EUROPEAN UROLOGY, vol. 36, no. SUPPL. 1, June 1999 (1999-06), pages 89-95, XP001094443 Pre-Congress Satellite Symposium on α -Adrenoceptors as Targets for Therapeutic Agents in Urology in connection with the XIIIth Congress of Pharmacology; Paris, France; Munich, Germany; July 23-24, 1998; July 26, 1998 ISSN: 0302-2838 * see in particular p. 89, right column, 3rd paragraph; p. 92, left column, 2nd last paragraph *	12-15

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 12-15 (all of them partially)

Present claims 12-15, as far as they depend on claims 1 and 6, relate to an extremely large number of possible compounds or formulations. The term "drugs used for the incontinence" used in claim 1 encompasses an unlimited group of compounds, which is permanently changing, so that a complete search is impossible. In fact, the claims contain so many options that a lack of conciseness within the meaning of Article 6 PCT arises. The same reasoning applies mutatis mutandis for the functional terms used in claim 6 for the groups B'1-B'9 and B'11 and in claim 1 for group C. Consequently, the search of claims 12-15 has been carried out for those parts of the application which do appear to be concise, namely for the concrete compounds mentioned in claims 6 (group B'10), 7 and 8.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claim : 12; 14 and 15 (partially)

Nitrate salts of drugs used for the incontinence and which do not contain in the molecule a nitric oxide donor group, formulations containing them and their use as a medicament.

2. Claim : 13; 14 and 15 (partially)

Organic or inorganic salts of compounds inhibiting phosphodiesterases, formulations containing them and their use as a medicament.

3. Claim : 14 (partially)

Formulations containing nitric oxide donor drugs, salified and non salified of formula $A-X1-N(O)_z$ as defined in claim 1 of the present application.

INTERNATIONAL SEARCH REPORT

In International Application No
PCT/EP 01/08734

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 1020190	A	JP 2000128804 A	09-05-2000
US 5525604	A	11-06-1996	
		AT 163647 T	15-03-1998
		CA 2130878 A1	27-02-1995
		CN 1109055 A	27-09-1995
		DE 69408750 D1	09-04-1998
		DE 69408750 T2	23-07-1998
		DK 640599 T3	28-09-1998
		EP 0640599 A1	01-03-1995
		ES 2114662 T3	01-06-1998
		JP 7089958 A	04-04-1995
		KR 204433 B1	15-06-1999
US 5436233	A	25-07-1995	
		AT 208771 T	15-11-2001
		CA 2100626 A1	16-01-1994
		DE 69331122 D1	20-12-2001
		DE 69331122 T2	20-06-2002
		DK 579496 T3	25-02-2002
		EP 0579496 A1	19-01-1994
		ES 2167325 T3	16-05-2002
		JP 2657760 B2	24-09-1997
		JP 6192235 A	12-07-1994
		JP 2923742 B2	26-07-1999
		JP 8099962 A	16-04-1996
		US 5439895 A	08-08-1995
		KR 191416 B1	15-06-1999
WO 9628448	A	19-09-1996	
		AU 708809 B2	12-08-1999
		AU 5093396 A	02-10-1996
		CA 2211729 A1	19-09-1996
		CZ 9702806 A3	15-04-1998
		EP 0813534 A1	29-12-1997
		HU 9801394 A2	28-10-1998
		JP 11501926 T	16-02-1999
		NO 974150 A	07-11-1997
		NZ 303886 A	25-11-1998
		PL 322452 A1	02-02-1998
		US 5958929 A	28-09-1999
		WO 9628448 A1	19-09-1996
		US 5736548 A	07-04-1998
		ZA 9601948 A	17-09-1996
EP 0943613	A	22-09-1999	
		AU 4967697 A	10-06-1998
		EP 0943613 A1	22-09-1999
		WO 9822455 A1	28-05-1998
WO 0051988	A	08-09-2000	
		IT MI990413 A1	04-09-2000
		AU 3158800 A	21-09-2000
		BR 0008582 A	13-02-2002
		CN 1342147 T	27-03-2002
		WO 0051988 A1	08-09-2000
		EP 1154999 A1	21-11-2001

INTERNATIONAL SEARCH REPORT

 International Application No
 PCT/EP 01/08734

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9809948	A	12-03-1998	IT MI961821 A1	04-03-1998
			AU 729533 B2	01-02-2001
			AU 4301097 A	26-03-1998
			BR 9712008 A	24-08-1999
			CN 1234792 A	10-11-1999
			WO 9809948 A2	12-03-1998
			EP 0931065 A2	28-07-1999
			JP 2000517332 T	26-12-2000
WO 9637202	A	28-11-1996	US 5674895 A	07-10-1997
			AU 695194 B2	06-08-1998
			AU 5639296 A	11-12-1996
			AU 718849 B2	20-04-2000
			AU 9052298 A	14-01-1999
			BE 1009462 A3	01-04-1997
			CA 2218714 A1	28-11-1996
			CH 690955 A5	15-03-2001
			DE 19681389 T0	23-04-1998
			FR 2734483 A1	29-11-1996
			GB 2318055 A , B	15-04-1998
			IT T0960427 A1	21-11-1997
			JP 11505264 T	18-05-1999
			NL 1003185 C2	03-12-1996
			NL 1003185 A1	25-11-1996
			NZ 307116 A	29-03-1999
			US 6124355 A	26-09-2000
			WO 9637202 A1	28-11-1996
			US 6262115 B1	17-07-2001
			US 5840754 A	24-11-1998
			US 2001005728 A1	28-06-2001
			US 5912268 A	15-06-1999
WO 0189473	A	29-11-2001	AU 4638901 A	15-10-2001
			AU 6008901 A	03-12-2001
			WO 0174335 A1	11-10-2001
			WO 0189473 A1	29-11-2001
US 6203817	B1	20-03-2001	NONE	
WO 9967231	A	29-12-1999	IT MI981408 A1	20-12-1999
			AU 4513999 A	10-01-2000
			BR 9911305 A	23-10-2001
			CN 1315945 T	03-10-2001
			WO 9967231 A1	29-12-1999
			EP 1087953 A1	04-04-2001
			HU 0102719 A2	28-12-2001
GB 2330579	A	28-04-1999	FR 2770519 A1	07-05-1999
EP 1092719	A	18-04-2001	BR 0004779 A	29-05-2001
			EP 1092719 A2	18-04-2001
			JP 2001151778 A	05-06-2001
DE 19540642	A	07-05-1997	DE 19540642 A1	07-05-1997
EP 1020190	A	19-07-2000	AU 5597799 A	04-05-2000
			EP 1020190 A2	19-07-2000
			HU 9903732 A2	28-08-2000